How we grade evidence
- L1 Multiple randomized controlled trials with consistent effect; systematic reviews support the intervention.
- L2 At least one RCT plus larger case series; effect direction consistent but magnitude debated.
- L3 Case series, small pilots, animal data extrapolated; plausible but unproven at scale.
- L4 Testimonial, marketing, or fringe-diagnosis claims without peer-reviewed evidence of benefit.
What TMJ dysfunction actually covers
"TMJ" is not a single diagnosis — it is a catch-all for temporomandibular joint dysfunction, which encompasses myofascial pain (masticatory muscles), internal derangement (disc displacement with or without reduction), and degenerative joint disease (osteoarthritis of the condyle or fossa). These have different treatments. Regenerative claims tend to blur the distinctions in ways that matter.
Standard first-line care is conservative: soft diet, thermal therapy, occlusal splint or bite guard, jaw exercises, cognitive-behavioral input for bruxism, and short courses of anti-inflammatories. Most TMJ pain resolves or becomes tolerable with these measures. Surgical intervention (arthrocentesis, arthroscopy, open joint procedures) is reserved for refractory internal derangement or late-stage degenerative disease.
Where regenerative therapy has been studied
PRP is the most-studied regenerative option for the TMJ. Multiple small trials — mostly in patients with degenerative TMJ disease — have compared PRP-augmented arthrocentesis to arthrocentesis with hyaluronic acid or saline. Results are inconsistent but generally favor PRP for pain and function at 3–6 months, with less clear differences at 12 months.
Cell therapy specifically for the TMJ is much less studied. A small number of case series report intra-articular MSC injections for degenerative TMJ, with reported symptom improvement. Sample sizes are small, follow-up short, and blinding largely absent. The evidence supports "plausibly useful adjunct in degenerative TMJ" and does not support "curative therapy for TMJ pain."
Where cell therapy might reasonably fit
- Degenerative TMJ (osteoarthritis) that has failed conservative care and PRP arthrocentesis.
- Post-surgical TMJ patients with persistent pain.
- Cases where the alternative is an open TMJ procedure — a substantial intervention.
Where it does not
Muscle-driven TMJ pain — the most common presentation, especially in patients with bruxism — is not obviously helped by intra-articular therapy of any kind. If your primary problem is masseter and temporalis tenderness rather than joint clicking or degenerative imaging findings, cell therapy is aimed at the wrong tissue.
Imaging and workup that legitimate clinics should require
Panoramic radiograph, cone-beam CT of the TMJ (for degenerative changes), and MRI (for disc position and joint effusion) are standard imaging. A dental or oromaxillofacial evaluation to rule out occlusal contributors is baseline. Clinics that inject TMJ joints without recent imaging and without a proper diagnostic workup are skipping the parts that determine whether the therapy has any chance of working.
If your TMJ pain is primarily driven by nighttime clenching or grinding, and that has not been addressed with a bite guard and behavioral input, injecting the joint is treating downstream symptoms. Cell therapy will not stop bruxism. This is a common reason regenerative TMJ work does not deliver expected results — the mechanical cause continues.
Regulatory status — TMJ dysfunction
TMJ pain that hasn't responded to conservative care?
Send us your workup and imaging on WhatsApp — we'll help you evaluate what's actually likely to help.
Ask a question on WhatsApp